Your browser doesn't support javascript.
loading
B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models.
Huang, Deli; Abbott, Robert K; Havenar-Daughton, Colin; Skog, Patrick D; Al-Kolla, Rita; Groschel, Bettina; Blane, Tanya R; Menis, Sergey; Tran, Jenny Tuyet; Thinnes, Theresa C; Volpi, Sabrina A; Liguori, Alessia; Schiffner, Torben; Villegas, Sophia M; Kalyuzhniy, Oleksandr; Pintea, Mark; Voss, James E; Phelps, Nicole; Tingle, Ryan; Rodriguez, Alberto R; Martin, Greg; Kupryianov, Sergey; deCamp, Allan; Schief, William R; Nemazee, David; Crotty, Shane.
Afiliação
  • Huang D; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
  • Abbott RK; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037.
  • Havenar-Daughton C; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.
  • Skog PD; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037.
  • Al-Kolla R; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.
  • Groschel B; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
  • Blane TR; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037.
  • Menis S; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
  • Tran JT; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.
  • Thinnes TC; International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, CA 92037.
  • Volpi SA; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
  • Liguori A; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
  • Schiffner T; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.
  • Villegas SM; International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, CA 92037.
  • Kalyuzhniy O; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
  • Pintea M; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
  • Voss JE; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
  • Phelps N; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
  • Tingle R; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.
  • Rodriguez AR; International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, CA 92037.
  • Martin G; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
  • Kupryianov S; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.
  • deCamp A; International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, CA 92037.
  • Schief WR; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
  • Nemazee D; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.
  • Crotty S; International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, CA 92037.
Proc Natl Acad Sci U S A ; 117(37): 22920-22931, 2020 09 15.
Article em En | MEDLINE | ID: mdl-32873644
Animal models of human antigen-specific B cell receptors (BCRs) generally depend on "inferred germline" sequences, and thus their relationship to authentic naive human B cell BCR sequences and affinities is unclear. Here, BCR sequences from authentic naive human VRC01-class B cells from healthy human donors were selected for the generation of three BCR knockin mice. The BCRs span the physiological range of affinities found in humans, and use three different light chains (VK3-20, VK1-5, and VK1-33) found among subclasses of naive human VRC01-class B cells and HIV broadly neutralizing antibodies (bnAbs). The germline-targeting HIV immunogen eOD-GT8 60mer is currently in clinical trial as a candidate bnAb vaccine priming immunogen. To attempt to model human immune responses to the eOD-GT8 60mer, we tested each authentic naive human VRC01-class BCR mouse model under rare human physiological B cell precursor frequency conditions. B cells with high (HuGL18HL) or medium (HuGL17HL) affinity BCRs were primed, recruited to germinal centers, and they affinity matured, and formed memory B cells. Precursor frequency and affinity interdependently influenced responses. Taken together, these experiments utilizing authentic naive human VRC01-class BCRs validate a central tenet of germline-targeting vaccine design and extend the overall concept of the reverse vaccinology approach to vaccine development.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos B / Anticorpos Anti-HIV / Anticorpos Amplamente Neutralizantes / Anticorpos Monoclonais Limite: Animals / Humans Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos B / Anticorpos Anti-HIV / Anticorpos Amplamente Neutralizantes / Anticorpos Monoclonais Limite: Animals / Humans Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2020 Tipo de documento: Article